Request Demo
Last update 04 Apr 2026
NN-8209
Last update 04 Apr 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms AntiC5aR151, NN 8209, NN8209 + [2] |
Target |
Action antagonists |
Mechanism C5AR1 antagonists(C5a anaphylatoxin chemotactic receptor antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with NN-8209NCT01223911
A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
NCT01018238
A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Multiple Site Study of Anti-C5a Receptor Antibody (NNC 0151-0000-0000) in Subjects With Systemic Lupus Erythematosus (SLE)
NCT02151409
A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.
100 Clinical Results associated with NN-8209
Login to view more data
100 Translational Medicine associated with NN-8209
Login to view more data
100 Patents (Medical) associated with NN-8209
Login to view more data
100 Deals associated with NN-8209
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Phase 2 | Czechia | 01 Jan 2011 | |
| Inflammation | Phase 2 | Denmark | 01 Jan 2011 | |
| Inflammation | Phase 2 | Hungary | 01 Jan 2011 | |
| Inflammation | Phase 2 | Poland | 01 Jan 2011 | |
| Inflammation | Phase 2 | Romania | 01 Jan 2011 | |
| Inflammation | Phase 2 | United Kingdom | 01 Jan 2011 | |
| Rheumatoid Arthritis | Phase 2 | Czechia | 01 Jan 2011 | |
| Rheumatoid Arthritis | Phase 2 | Denmark | 01 Jan 2011 | |
| Rheumatoid Arthritis | Phase 2 | Hungary | 01 Jan 2011 | |
| Rheumatoid Arthritis | Phase 2 | Poland | 01 Jan 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free